S&P 500   5,161.48 (-0.72%)
DOW   38,218.57 (-0.63%)
QQQ   441.71 (-0.82%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)
S&P 500   5,161.48 (-0.72%)
DOW   38,218.57 (-0.63%)
QQQ   441.71 (-0.82%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)
S&P 500   5,161.48 (-0.72%)
DOW   38,218.57 (-0.63%)
QQQ   441.71 (-0.82%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)
S&P 500   5,161.48 (-0.72%)
DOW   38,218.57 (-0.63%)
QQQ   441.71 (-0.82%)
AAPL   177.47 (+1.39%)
MSFT   424.31 (-0.85%)
META   516.20 (-1.33%)
GOOGL   159.28 (-0.08%)
AMZN   187.98 (-0.57%)
TSLA   172.89 (-0.98%)
NVDA   894.47 (-1.29%)
AMD   162.69 (-4.58%)
NIO   4.23 (-5.16%)
BABA   72.77 (-2.78%)
T   16.43 (+0.06%)
F   12.86 (-1.38%)
MU   124.69 (-2.21%)
GE   156.25 (-0.73%)
CGC   8.17 (+0.25%)
DIS   115.79 (-1.16%)
AMC   2.74 (-2.14%)
PFE   26.26 (-0.30%)
PYPL   65.73 (-0.11%)
XOM   123.54 (+1.44%)
NASDAQ:BDSX

Biodesix (BDSX) Stock Price, News & Analysis

$1.26
+0.02 (+1.61%)
(As of 09:48 AM ET)
Today's Range
$1.25
$1.26
50-Day Range
$1.23
$2.12
52-Week Range
$1.03
$2.21
Volume
4,035 shs
Average Volume
159,486 shs
Market Capitalization
$122.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

Biodesix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
182.3% Upside
$3.50 Price Target
Short Interest
Healthy
1.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Biodesix in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$173,034 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to ($0.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

1534th out of 2,784 stocks

Medical Laboratories Industry

34th out of 57 stocks

BDSX stock logo

About Biodesix Stock (NASDAQ:BDSX)

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

BDSX Stock Price History

BDSX Stock News Headlines

S&P 500 Gains Over 1%; GCT Semiconductor Shares Spike Higher
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Gold Surges Over 1%; Biodesix Shares Plummet
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Biodesix Inc CEO Scott Hutton Sells 64,390 Shares
Here's what Wall Street expects from Biodesix's earnings
Jack Schuler Spends US$217k On Biodesix Stock
See More Headlines
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2024
Today
4/11/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BDSX
Fax
N/A
Employees
217
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$3.50
Low Stock Price Target
$3.50
Potential Upside/Downside
+182.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-52,150,000.00
Net Margins
-106.23%
Pretax Margin
-106.23%
Return on Equity
-29,379.44%

Debt

Sales & Book Value

Annual Sales
$49.09 million
Book Value
$0.05 per share

Miscellaneous

Free Float
35,093,000
Market Cap
$120.21 million
Optionable
Optionable
Beta
1.13
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives


BDSX Stock Analysis - Frequently Asked Questions

Should I buy or sell Biodesix stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDSX shares.
View BDSX analyst ratings
or view top-rated stocks.

What is Biodesix's stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for Biodesix's shares. Their BDSX share price targets range from $3.50 to $3.50. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 182.3% from the stock's current price.
View analysts price targets for BDSX
or view top-rated stocks among Wall Street analysts.

How have BDSX shares performed in 2024?

Biodesix's stock was trading at $1.84 at the start of the year. Since then, BDSX stock has decreased by 32.6% and is now trading at $1.24.
View the best growth stocks for 2024 here
.

Are investors shorting Biodesix?

Biodesix saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 277,400 shares, an increase of 53.2% from the March 15th total of 181,100 shares. Based on an average daily trading volume, of 163,400 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.1% of the company's shares are sold short.
View Biodesix's Short Interest
.

When is Biodesix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BDSX earnings forecast
.

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) announced its quarterly earnings data on Friday, March, 1st. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm earned $14.67 million during the quarter, compared to analysts' expectations of $15.76 million. Biodesix had a negative trailing twelve-month return on equity of 29,379.44% and a negative net margin of 106.23%.

What guidance has Biodesix issued on next quarter's earnings?

Biodesix issued an update on its FY 2024 earnings guidance on Friday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $65.0 million-$68.0 million, compared to the consensus revenue estimate of $64.5 million.

When did Biodesix IPO?

Biodesix (BDSX) raised $76 million in an initial public offering on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

How do I buy shares of Biodesix?

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BDSX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners